Pharmacokinetics of midazolam in patients recovering from cardiac surgery
- PMID: 2792170
- DOI: 10.1007/BF00558225
Pharmacokinetics of midazolam in patients recovering from cardiac surgery
Abstract
The pharmacokinetics of midazolam has been studied in patients recovering from cardiac surgery, who required sedation for postoperative mechanical ventilation. Twelve males (mean age 64.5 years) with severe heart disease received an infusion of midazolam 15 mg.h-1 for 4 h, starting 1 to 3 h post surgery. Multiple blood samples were collected from each patient during the infusion and up to 48-93 h after it. The pharmacokinetic parameters of midazolam were determined using both moment analysis and the program NONMEM. The average terminal half-life was 10.6 h. The prolonged elimination was mainly due to a decrease in its metabolic clearance (0.25 l.min-1). The maintenance infusion dose of midazolam in such patients should be reduced. The time to recovery after stopping an infusion depends upon the amount of drug in the body at that time and a simulation of the plasma concentrations after various infusion regimens suggests that recovery will be delayed after prolonged (greater than 48 h) administration of midazolam to these patients. However, after shorter infusions (less than 12 h), redistribution of the drug away from the site of action was still occurring and recovery would be expected to be relatively rapid.
Similar articles
-
Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.Anesthesiology. 1998 Dec;89(6):1418-29. doi: 10.1097/00000542-199812000-00020. Anesthesiology. 1998. PMID: 9856717 Clinical Trial.
-
Postoperative sedation with midazolam in heart surgery patients: pharmacokinetic considerations.Acta Anaesthesiol Scand Suppl. 1990;92:103-6. doi: 10.1111/j.1399-6576.1990.tb03195.x. Acta Anaesthesiol Scand Suppl. 1990. PMID: 2183536 Review.
-
Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery.Br J Anaesth. 2007 Aug;99(2):252-61. doi: 10.1093/bja/aem135. Epub 2007 Jun 19. Br J Anaesth. 2007. PMID: 17578905 Clinical Trial.
-
Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion.Can J Anaesth. 1994 Sep;41(9):782-93. doi: 10.1007/BF03011584. Can J Anaesth. 1994. PMID: 7954994 Clinical Trial.
-
Clinical pharmacokinetic monitoring of midazolam in critically ill patients.Pharmacotherapy. 2007 Mar;27(3):389-98. doi: 10.1592/phco.27.3.389. Pharmacotherapy. 2007. PMID: 17316150 Review.
Cited by
-
Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison.Intensive Care Med. 1997 Dec;23(12):1258-63. doi: 10.1007/s001340050495. Intensive Care Med. 1997. PMID: 9470082 Clinical Trial.
-
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.Clin Pharmacokinet. 2022 Nov;61(11):1595-1607. doi: 10.1007/s40262-022-01175-6. Epub 2022 Oct 4. Clin Pharmacokinet. 2022. PMID: 36195807 Free PMC article. Clinical Trial.
-
Comparative tolerability of sedative agents in head-injured adults.Drug Saf. 2004;27(2):107-33. doi: 10.2165/00002018-200427020-00003. Drug Saf. 2004. PMID: 14717622 Review.
-
Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.Can J Anaesth. 1993 Dec;40(12):1178-94. doi: 10.1007/BF03009608. Can J Anaesth. 1993. PMID: 8281595 Review.
-
A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.J Pharmacokinet Biopharm. 1991 Aug;19(4):377-84. doi: 10.1007/BF01061662. J Pharmacokinet Biopharm. 1991. PMID: 1920085
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous